Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 in Hepatocellular Carcinoma
NCT00056992Phase 2Completed
- Sponsor
- Food and Drug Administration
- Start
- Sep 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Pegargiminase in hepatocellular carcinoma (HCC), sponsored by Food and Drug Administration. Primary endpoint: Efficacy. Started Sep 2002; status: completed.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00056992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056992.